StockNews.com cut shares of CEL-SCI (NYSEAMERICAN:CVM – Free Report) from a hold rating to a sell rating in a research note released on Monday morning. Separately, EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a $10.00 price target on shares of CEL-SCI in a report on Thursday, March 9th. CEL-SCI Stock Up […]
StockNews.com downgraded shares of CEL-SCI (NYSEAMERICAN:CVM – Get Rating) from a hold rating to a sell rating in a report released on Sunday. Separately, EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a $10.00 price target on shares of CEL-SCI in a report on Thursday, March 9th. CEL-SCI Price Performance NYSEAMERICAN CVM […]
CEL-SCI (NYSEAMERICAN:CVM – Get Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Sunday. Separately, EF Hutton Acquisition Co. I restated a “buy” rating and set a $10.00 price objective on shares of CEL-SCI in a research report on Thursday, March 9th. CEL-SCI […]
CEL-SCI (NYSE:CVM – Get Rating) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Monday. CEL-SCI Stock Performance About CEL-SCI (Get Rating) CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and […]
CEL-SCI Corporation (NYSE American: CVM) today announced it will present the new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN), at the Americ.